Table 3.
Diagnostic utility of EBUS‐TBNA (per patient analysis) in study cohort (extrathoracic cancers and all lung cancers), all NSCLC cases and stages
| Cohort | Number of patients | Number of nodes | PET | Mean EBUS node size (mm) | Sensitivity (%) | Accuracy (%) | NPV (%) | Prevalence (%) |
|---|---|---|---|---|---|---|---|---|
| Whole study cohort | 284 | 503 | 56 | 21.2 | 95.7 | 96.5 | 83.3 | 82.4 |
| NSCLC only (combined) | 200† | 349 | 51 | 20.3 | 94.3 | 95.7 | 85.5 | 74.8 |
| NSCLC Stage I & II | 28 (14%) | 42 | 17 | 17.4 | 93.8 | 96.4 | 92.3 | 57.1 |
| NSCLC Stage IIIa | 65 (32.5%) | 119 | 18 | 19.3 | 94.1 | 95.4 | 82.4 | 78.5 |
| NSCLC Stage IIIb | 33 (16.5%) | 73 | 8 | 22.0 | 96.8 | 97 | 66.7 | 93.9 |
| NSCLC Stage IV | 74 (37%) | 125 | 8 | 20.9 | 93.2 | 94.6 | 79.0 | 79.7 |
†
Includes all non‐small cell lung cancer (NSCLC) cases, including true negative and false negative cases.
EBUS‐TNA, endobronchial ultrasound‐guided transbronchial needle aspiration; NPV, negative predictive value; PET, positron emission tomography.